A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight
Amgen
180 participants
Mar 5, 2026
INTERVENTIONAL
Conditions
Summary
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
Eligibility
Inclusion Criteria9
- Age ≥ 18 years.
- Body Mass index (BMI) ≥ 27 kg/m\^2 to ≤ 40 kg/m\^2 at screening.
- For participants with type 2 diabetes mellitus (T2DM) at screening:
- HbA1c ≤ 9.5% (80 mmol/mol) at screening.
- Treated with diet and exercise alone and/or a stable treatment with metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, or combination.
- Liver Controlled Attenuation Parameter (CAPTM) ≥ 300 dB/meter via FibroScan® assessment.
- Liver fat content ≥ 10% by MRI as determined by the central imaging vendor at screening.
- MRI assessment should only be performed after all other eligibility has been confirmed whenever possible.
- History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.
Exclusion Criteria13
- Recent or planned surgical/device-based obesity treatment (\<1 year).
- History of malignancy within the past 5 years (exceptions apply).
- Type 1 diabetes or non-type 2 diabetes mellitus (T2DM); unstable/severe hypoglycemia.
- Advanced diabetic retinopathy or macular edema.
- History of pancreatitis (acute \<180 days or chronic).
- History of medullary thyroid carcinoma (MTC) or MEN-2
- Major cardiovascular event within 60 days (e.g., myocardial infarction \[MI\], stroke, coronary artery bypass graft \[CABG\]).
- New York Heart Association (NYHA) Class IV heart failure.
- Unstable psychiatric disorders within 2 years.
- Significant liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD) (e.g., hepatitis, cirrhosis, hepatic decompensation).
- Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2 or on dialysis.
- Patient Health Questionnaire-9 (PHQ-9) ≥ 15, or suicidal ideation/behavior (Columbia-Suicide Severity Rating Scale \[C-SSRS\]).
- Inability to undergo MRI scan (e.g., due to metal implant, claustrophobia, or body size limitations).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Maridebart cafraglutide will be administered as a SC injection.
Placebo will be administered as a SC injection.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07441252